Next earnings date: 4 Aug 2025
Anavex Life Sciences Corp. – NASDAQ:AVXL
Anavex Life Sciences Corp. stock price today
$9.7
-2.41
-19.9%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Anavex Life Sciences Corp. stock price monthly change
+124.67%
month
Anavex Life Sciences Corp. stock price quarterly change
+124.67%
quarter
Anavex Life Sciences Corp. stock price yearly change
+22.20%
year
Anavex Life Sciences Corp. key metrics
Market Cap | 900.10M |
Enterprise value | N/A |
P/E | -12.78 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 4.42 |
PEG ratio | 0.86 |
EPS | -0.57 |
Revenue | N/A |
EBITDA | -47.75M |
Income | -45.07M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAnavex Life Sciences Corp. stock price history
Anavex Life Sciences Corp. stock forecast
Anavex Life Sciences Corp. financial statements
| Mar 2023 | 0 | -13.10M | |
|---|---|---|---|
| Jun 2023 | 0 | -11.27M | |
| Sep 2023 | 0 | -10.14M | |
| Mar 2024 | 0 | -10.54M |
| Sep 2023 | 0 | -10.14M | |
|---|---|---|---|
| Mar 2024 | 0 | -10.54M | |
| Sep 2025 | 111.56M | -16.41M | -14.71% |
| Oct 2025 | 111.56M | -14.84M | -13.31% |
Analysts Price target
Financials & Ratios estimates
| 2024-08-06 | -0.15 | -0.14 |
|---|
| Mar 2023 | 159186397 | 14.02M | 8.81% |
|---|---|---|---|
| Jun 2023 | 157809863 | 11.05M | 7.01% |
| Sep 2023 | 154386000 | 12.53M | 8.12% |
| Mar 2024 | 144750000 | 9.55M | 6.6% |
| Mar 2023 | -8.48M | 0 | 18.33M |
|---|---|---|---|
| Jun 2023 | -7.65M | 0 | 9.00M |
| Sep 2023 | -5.84M | 0 | 2.05M |
| Mar 2024 | -11.65M | 0 | 7.27M |
Anavex Life Sciences Corp. alternative data
| Aug 2023 | 38 |
|---|---|
| Sep 2023 | 38 |
| Oct 2023 | 38 |
| Nov 2023 | 38 |
| Dec 2023 | 38 |
| Jan 2024 | 38 |
| Feb 2024 | 38 |
| Apr 2024 | 38 |
| May 2024 | 38 |
| Jun 2024 | 40 |
| Jul 2024 | 40 |
Anavex Life Sciences Corp. other data
30.00%
-35.47%
of AVXL is owned by hedge funds
91
-45
12.34M
-14.59M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 73380 |
| May 2024 | 5000 | 0 |
| Jun 2024 | 2835 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | DONHAUSER PETER D.O. director | Common Stock | 2,835 | $3.64 | $10,319 | ||
Purchase | THOMAS STEFFEN director | Common Stock | 5,000 | $4.52 | $22,600 | ||
Option | MISSLING CHRISTOPHER U director, officer.. | Common Stock | 73,380 | $1.32 | $96,862 | ||
Sale | MISSLING CHRISTOPHER U director, officer.. | Common Stock | 73,380 | $5.11 | $374,972 | ||
Option | MISSLING CHRISTOPHER U director, officer.. | Stock Option (Right to Buy) | 73,380 | $1.32 | $96,862 | ||
Option | MISSLING CHRISTOPHER U director, officer.. | Common Stock | 232,000 | $1.6 | $371,200 | ||
Option | MISSLING CHRISTOPHER U director, officer.. | Stock Option (Right to Buy) | 232,000 | $1.6 | $371,200 | ||
Option | MISSLING CHRISTOPHER U director, officer.. | Common Stock | 268,000 | $1.6 | $428,800 | ||
Sale | MISSLING CHRISTOPHER U director, officer.. | Common Stock | 268,000 | $7.98 | $2,139,444 | ||
Option | MISSLING CHRISTOPHER U director, officer.. | Stock Option (Right to Buy) | 268,000 | $1.6 | $428,800 |
| Quarter | Transcript |
|---|---|
| Q2 2024 9 May 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 7 Feb 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Nov 2023 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Aug 2023 | Q3 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Christopher U. Missling (1966) Chairman, Pres, Chief Executive Officer & Sec. | $671,600 |
Ms. Sandra Boenisch CPA, CPA, CGA (1981) Principal Financial Officer & Treasurer | $158,300 |
The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)
Undercovered Dozen: VICI Properties, General Dynamics, LandBridge, Anavex +
Playing The Odds Of Anavex Alzheimer's Drug Approval
The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease
Anavex Life Sciences: Jumping In On Time Ahead Of An Early Alzheimer's Decision
Acadia Pharmaceuticals: Back In The Buy Zone
Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box
Alzheimer's Disease Drug Development: Another Lost Year
Anavex Alzheimer's And Parkinson's Drug Underappreciated By Investors
-
What's the price of Anavex Life Sciences Corp. stock today?
One share of Anavex Life Sciences Corp. stock can currently be purchased for approximately $9.7.
-
When is Anavex Life Sciences Corp.'s next earnings date?
Anavex Life Sciences Corp. is estimated to report earnings on Monday, 4 Aug 2025.
-
Does Anavex Life Sciences Corp. pay dividends?
No, Anavex Life Sciences Corp. does not pay dividends.
-
How much money does Anavex Life Sciences Corp. make?
Anavex Life Sciences Corp. has a market capitalization of 900.10M. Anavex Life Sciences Corp. made a loss 43M US dollars in net income (profit) last year or -$0.14 on an earnings per share basis.
-
What is Anavex Life Sciences Corp.'s stock symbol?
Anavex Life Sciences Corp. is traded on the NASDAQ under the ticker symbol "AVXL".
-
What is Anavex Life Sciences Corp.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Anavex Life Sciences Corp.?
Shares of Anavex Life Sciences Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Anavex Life Sciences Corp.'s key executives?
Anavex Life Sciences Corp.'s management team includes the following people:
- Dr. Christopher U. Missling Chairman, Pres, Chief Executive Officer & Sec.(age: 59, pay: $671,600)
- Ms. Sandra Boenisch CPA, CPA, CGA Principal Financial Officer & Treasurer(age: 44, pay: $158,300)
-
How many employees does Anavex Life Sciences Corp. have?
As Jul 2024, Anavex Life Sciences Corp. employs 40 workers, which is 5% more then previous quarter.
-
When Anavex Life Sciences Corp. went public?
Anavex Life Sciences Corp. is publicly traded company for more then 19 years since IPO on 2 Aug 2006.
-
What is Anavex Life Sciences Corp.'s official website?
The official website for Anavex Life Sciences Corp. is anavex.com.
-
Where are Anavex Life Sciences Corp.'s headquarters?
Anavex Life Sciences Corp. is headquartered at 51 West 52nd Street, New York, NY.
-
How can i contact Anavex Life Sciences Corp.?
Anavex Life Sciences Corp.'s mailing address is 51 West 52nd Street, New York, NY and company can be reached via phone at +84 46893939.
Anavex Life Sciences Corp. company profile:
Anavex Life Sciences Corp.
anavex.comExchange:
NASDAQ
Full time employees:
40
Industry:
Biotechnology
Sector:
Healthcare
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
51 West 52nd Street
New York, NY 10019
New York, NY 10019
CIK: 0001314052
ISIN: US0327973006
CUSIP: 032797300
